CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
43.30
-1.43 (-3.20%)
At close: Dec 5, 2025, 4:00 PM EST
43.67
+0.37 (0.85%)
After-hours: Dec 5, 2025, 6:24 PM EST
CG Oncology Revenue
CG Oncology had revenue of $1.67M in the quarter ending September 30, 2025, with 3,774.42% growth. This brings the company's revenue in the last twelve months to $2.17M, up 217.84% year-over-year. In the year 2024, CG Oncology had annual revenue of $1.14M with 458.33% growth.
Revenue (ttm)
$2.17M
Revenue Growth
+217.84%
P/S Ratio
1,606.64
Revenue / Employee
$19,239
Employees
113
Market Cap
3.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.14M | 935.00K | 458.33% |
| Dec 31, 2023 | 204.00K | 13.00K | 6.81% |
| Dec 31, 2022 | 191.00K | -10.17M | -98.16% |
| Dec 31, 2021 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCGON News
- 1 day ago - New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 10 days ago - CG Oncology Announces New Board Member and Board Transition - GlobeNewsWire
- 22 days ago - CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic? - Seeking Alpha
- 2 months ago - Why Cg Oncology Stock Rocketed 7% Higher Today - The Motley Fool
- 3 months ago - CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 3 months ago - CG Oncology Stock Signals Bullish Momentum Ahead - Benzinga
- 3 months ago - CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months - GlobeNewsWire